According to the World Health Organization, 7 to 8 million people in LMICs learn their cancer is beyond curative treatment every year. That gap compared to high-income countries is not closing. It is widening.

OncoInv was founded to address this. The company is a multi-cancer detection technology provider, built on the belief that detection only creates real value when embedded in a structured programme with defined target populations, clinical follow-up pathways, and integration into existing healthcare settings.

Its technology, OncoSeek®, analyses proteins, tumor markers and circulating tumor DNA from a single blood draw. An AI model interprets the relationships between these biomarkers to generate a probability of cancer score and, where possible, an indication of tissue of origin across nine cancer types. The platform builds on laboratory infrastructure and biomarkers already in clinical use, making it deployable in healthcare settings where resources are limited.

OncoInv is already active across multiple markets through authorised distribution and implementation partners. A test alone does not create impact. What matters is how detection technology is embedded in local healthcare settings, how clinical adoption is driven, and how real-world evidence is generated over time.

Our mission is straightforward: to ensure that where you live does not determine whether cancer is found in time.